Sugi Predict

Sugi Predict / Compounds / SCHEMBL1369401

SCHEMBL1369401

SCHEMBL1369401

O=C(NO)c1ccc(OCCN2C(=O)c3ccccc3Oc3ccccc32)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 6/20 0.56
▸ HDAC6 Q9UBN7 6/20 0.56
▸ HDAC3 O15379 5/20 0.56
▸ HDAC2 Q92769 5/20 0.56
▸ HDAC7 Q8WUI4 4/20 0.56
▸ TUBB4A P04350 3/20 0.56
▸ TUBB P07437 3/20 0.56
▸ TUBA3C P0DPH7 3/20 0.56
▸ HDAC4 P56524 3/20 0.56
▸ TUBA1B P68363 3/20 0.56
▸ TUBA4A P68366 3/20 0.56
▸ TUBB4B P68371 3/20 0.56
▸ TUBB3 Q13509 3/20 0.56
▸ TUBB2A Q13885 3/20 0.56
▸ TUBB8 Q3ZCM7 3/20 0.56
▸ TUBA3E Q6PEY2 3/20 0.56
▸ TUBA1A Q71U36 3/20 0.56
▸ HDAC10 Q969S8 3/20 0.56
▸ HDAC11 Q96DB2 3/20 0.56
▸ TUBA1C Q9BQE3 3/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1367914 0.89 NPC1 (0.47) HDAC1HDAC6HDAC3HDAC2HDAC7
SCHEMBL1365088 0.89 HDAC1 (0.46) HDAC1HDAC6HDAC3HDAC2HDAC7
SCHEMBL1368168 0.89 HDAC1 (0.52) HDAC1HDAC6HDAC3HDAC2HDAC7
SCHEMBL1365852 0.89 HDAC8 (0.53) HDAC1HDAC6HDAC3HDAC2HDAC7
SCHEMBL1368266 0.88 TP53 (0.51) HDAC1HDAC6HDAC3HDAC2HDAC7
SCHEMBL16577637 0.87 HEXA (0.52) HDAC1HDAC6HDAC3HDAC2HDAC7
SCHEMBL2143884 0.84 HDAC3 (0.51) HDAC1HDAC6HDAC3HDAC2HDAC7
SCHEMBL2143874 0.84 HDAC1 (0.51) HDAC1HDAC6HDAC3HDAC2HDAC7
SCHEMBL2143776 0.84 HDAC1 (0.51) HDAC1HDAC6HDAC3HDAC2HDAC7
SCHEMBL1365197 0.82 HDAC1 (0.63) HDAC1HDAC6HDAC3HDAC2HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170000749-A1 Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase FMR LLC 2017-01-05 — — US disclosed
US-20170000749-A1 Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase FMR LLC 2017-01-05 — — US disclosed
US-20160222026-A1 Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors FMR LLC 2016-08-04 — — US disclosed
US-20160222026-A1 Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors FMR LLC 2016-08-04 — — US disclosed
US-20160222026-A1 Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors FMR LLC 2016-08-04 — — US disclosed
EP-2966078-A2 Inhibitors of histone deacetylase MethylGene Inc. (CA) 2016-01-13 — — EP disclosed
EP-2966078-A2 Inhibitors of histone deacetylase MethylGene Inc. (CA) 2016-01-13 — — EP disclosed
US-9193749-B2 Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors FORUM PHARMACEUTICALS, INC. (US) 2015-11-24 — — US disclosed
US-9193749-B2 Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors FORUM PHARMACEUTICALS, INC. (US) 2015-11-24 — — US disclosed
US-9193749-B2 Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors FORUM PHARMACEUTICALS, INC. (US) 2015-11-24 — — US disclosed
US-20110288070-A1 METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE FMR LLC 2011-11-24 — — US disclosed
US-20110288070-A1 METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE FMR LLC 2011-11-24 — — US disclosed
US-20110196147-A1 INHIBITORS OF HISTONE DEACETYLASE FMR LLC 2011-08-11 — — US disclosed
US-20110196147-A1 INHIBITORS OF HISTONE DEACETYLASE FMR LLC 2011-08-11 — — US disclosed
US-20110196147-A1 INHIBITORS OF HISTONE DEACETYLASE FMR LLC 2011-08-11 — — US disclosed
EP-2343286-A1 Dibenzo[b,f][1,4]oxazepine derivatives as inhibitors of histone deacetylase Methylgene, Inc. (CA) 2011-07-13 — — EP disclosed
EP-2343286-A1 Dibenzo[b,f][1,4]oxazepine derivatives as inhibitors of histone deacetylase Methylgene, Inc. (CA) 2011-07-13 — — EP disclosed
US-20080207590-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2008-08-28 — — US disclosed
US-20080207590-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2008-08-28 — — US disclosed
US-20080207590-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2008-08-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110288070-A1 METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE HDAC1, HDAC5, HDAC2 HDAC1 1/4885HDAC6 9/4885HDAC3 14/4885
US-20080207590-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC5, HDAC11 HDAC1 1/4885HDAC6 11/4885HDAC3 4/4885
US-20170000749-A1 Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase HDAC5, KAT2A, HDAC1 HDAC1 3/4885HDAC6 11/4885HDAC3 15/4885
US-20160222026-A1 Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors HDAC1, HDAC2, HDAC4 HDAC1 1/4885HDAC6 9/4885HDAC3 7/4885
US-20110196147-A1 INHIBITORS OF HISTONE DEACETYLASE HDAC1, HDAC5, HDAC11 HDAC1 1/4885HDAC6 11/4885HDAC3 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.